Non-invasive Trigeminal and Vagus Nerve Stimulation for Stroke Subjects With Chronic Upper Extrem… (NCT06288217) | Clinical Trial Compass
UnknownNot Applicable
Non-invasive Trigeminal and Vagus Nerve Stimulation for Stroke Subjects With Chronic Upper Extremity Deficits
United States25 participantsStarted 2024-03-05
Plain-language summary
This is a single-center, pilot study of up to 25 subjects with residual upper extremity deficits at least six months after an ischemic stroke. The purpose of the study is to evaluate the initial clinical safety, device functionality, and treatment effect of non-invasive electrical stimulation of the trigeminal and/or vagus nerves (nTVNS) using the NeuraStasis Stimulator System adjunctive to rehabilitation. Subjects will either receive the intervention or control-sham stimulation. The study will inform the design and implementation of a pivotal study.
Who can participate
Age range40 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* History of unilateral supratentorial ischemic stroke that occurred at least 6 months but not more than 10 years prior to enrollment.
* Age \>40 years and \<80 years.
* Fugl-Meyer Assessment, Upper Limb (FMA-UE) baseline score of 20 to 50 (inclusive of 20 and 50).
* Ability to communicate, understand, and provide appropriate consent. Subjects should be able to follow two-step commands.
* Right- or left-sided weakness of the upper extremity.
Exclusion Criteria
* Participant has implanted metallic or electronic devices in the head or neck
* Hemorrhagic stroke or a heterogenous lesion etiology
* Participant has a cardiac pacemaker or implanted or wearable defibrillator
* Participant skin in the stimulation area has open wounds, skin eruptions, swollen, infected, or inflamed areas, or skin abnormalities that could be cancerous
* Advanced cardiac, pulmonary, liver, kidney dysfunction or blood system disease
* Participant has a fever or shows clinical signs concerning for an infectious disease
* Other neurologic or musculoskeletal diseases that could interfere with the assessments of this study
* Low heart rate (\<60 bpm) from a cardiac conduction block or related etiology
* Participant has a history of trigeminal neuralgia
* Participant has a history of Bell's Palsy
* History of cranial nerve neuropathy (including facial nerve injury), carotid surgery, vagotomy, or other surgical intervention on the vagus nerve
* History of recurrent syncopal events
* Known…
What they're measuring
1
Fugl-Meyer Assessment, Upper Limb (FMA-UE) Average Change
Timeframe: Within 7 days of completing 6 weeks of rehabilitation